original ) (raw )Von Willebrand Factor:Antigen And Adamts-13 Level, But Not Soluble P-Selectin, Are Risk Factors For The First Asymptomatic Deep Vein Thrombosis In Cancer Patients Undergoing Chemotherapy
eko pangarsa
View PDFchevron_right
High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)
Daniela Dunkler
Blood, 2008
View PDFchevron_right
Soluble P-selectin and correlation with Prothrombin Fragment 1 + 2 in myeloid malignancies in Cipto Mangunkusumo general hospital
Lugyanti Sukrisman
Thrombosis Journal, 2021
View PDFchevron_right
Differential biomarker profiles between unprovoked venous thromboembolism and cancer
Remedios Otero Candelera
Annals of Medicine, 2020
View PDFchevron_right
P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface
Bahman Anvari
Blood, 2004
View PDFchevron_right
High Concentrations of Soluble P-Selectin Are Associated with Risk of Venous Thromboembolism and the P-Selectin Thr715 Variant
S. Panzer
Clinical Chemistry, 2007
View PDFchevron_right
P-selectin in arterial thrombosis
Perumal Thiagarajan
Zeitschrift f�r Kardiologie, 2004
View PDFchevron_right
Cancer-Associated Thrombosis: Risk Factors, Molecular Mechanisms, Future Management
Shaker Mousa
Clinical and Applied Thrombosis/Hemostasis, 2020
View PDFchevron_right
Effects of heparin and aspirin on circulating P-selectin, E-selectin and von Willebrand Factor levels in healthy men
Petra Jilma-stohlawetz
Atherosclerosis, 2001
View PDFchevron_right
Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients—a pilot study
Fiorella Guadagni
Supportive Care in Cancer, 2012
View PDFchevron_right
P-Selectin Inhibition Therapeutically Promotes Thrombus Resolution and Prevents Vein Wall Fibrosis Better Than Enoxaparin and an Inhibitor to von Willebrand Factor
Shirley Wrobleski , José Diaz , K. Roelofs , N. Doornbos
Arteriosclerosis, Thrombosis, and Vascular Biology, 2015
View PDFchevron_right
Decreased venous thrombosis with an oral inhibitor of P selectin
Shirley Wrobleski
Journal of Vascular Surgery, 2005
View PDFchevron_right
Correlation of Inflammation and Coagulation Markers with the Incidence of Deep Vein Thrombosis in Cancer Patients with High Risk of Thrombosis
eko pangarsa
International Journal of General Medicine
View PDFchevron_right
Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial
Joseph Tomson
Journal of Internal Medicine, 2007
View PDFchevron_right
The incidence of occult cancer in patients with deep venous thrombosis: a prospective study
Anastasios Karayiannakis
Journal of Internal Medicine, 1996
View PDFchevron_right
P-Selectin As A Marker of Platelet Activation in Africans with Prostate Cancer: A Cross-Sectional Study
Hannah Omunakwe
IOSR Journal of Dental and Medical Sciences, 2016
View PDFchevron_right
Selectins Influence Thrombosis in a Mouse Model of Experimental Deep Venous Thrombosis
Shirley Wrobleski
Journal of Surgical Research, 2002
View PDFchevron_right
Anticancer treatment and thrombosis
Marina Marchetti , Anna Falanga
Thrombosis Research, 2012
View PDFchevron_right
Von Willebrand Factor, Soluble P-Selectin, and Target Organ Damage in Hypertension: A Substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
David Gurney
Hypertension, 2002
View PDFchevron_right
Change in plasma a disintegrin and metalloprotease with thrombospondin type-1 repeats-13 and von Willebrand factor levels in venous thromboembolic patients
Anil Tombak
Hematology, 2016
View PDFchevron_right
Prognostic Value of Plasma von Willebrand Factor and Soluble P-Selectin as Indices of Endothelial Damage and Platelet Activation in 994 Patients With Nonvalvular Atrial Fibrillation
Lesly A Pearce
Circulation, 2003
View PDFchevron_right
Thrombophilic state in cancer, Part I: Biology, incidence, and risk factors
Frederick Moffat , Subhasis Misra
Journal of Surgical Oncology, 2011
View PDFchevron_right
Anticoagulants in thrombosis and cancer: the missing link
Shaker Mousa
Expert Review of Anticancer Therapy, 2002
View PDFchevron_right
Treatment of venous thromboembolism in patients with cancer: Subgroup analysis of the Matisse clinical trials
Anna Falanga
Thrombosis and Haemostasis, 2009
View PDFchevron_right
D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study
Alexandru Chiriac
Journal of Clinical Oncology, 2009
View PDFchevron_right
Thrombosis and Cancer
Bülent Berkarda
Turkish journal of haematology : official journal of Turkish Society of Haematology, 2002
View PDFchevron_right
Cancer Therapy–Associated Thrombosis
Raj Kasthuri
Arteriosclerosis, Thrombosis, and Vascular Biology, 2021
View PDFchevron_right
Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression
Martine Jandrot-perrus
Haematologica, 2018
View PDFchevron_right
Nanoparticles of a New Small-Molecule P-Selectin Inhibitor Attenuate Thrombosis, Inflammation, and Tumor Growth in Two Animal Models
Eldar Muhtar
International Journal of Nanomedicine, 2021
View PDFchevron_right
Antithrombotics in thrombosis and cancer
Shaker Mousa
Expert Review of Cardiovascular Therapy, 2003
View PDFchevron_right